Patients & Physicians

Translating our knowledge of cellular metabolism into new medicines that improve the lives of patients.

At Imbria, our mission is to translate our understanding of cellular metabolism into medicines that improve the lives of patients with limited or inadequate treatment options.

We are currently advancing treatments that can help enhance or restore energy-related cellular functions necessary to thrive. 

Imbria is focused on cardiometabolic disorders

Non-obstructive hypertrophic cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiomyopathy with a prevalence in the general population of 1:200. Among clinically recognized patients, HCM may be compatible with normal longevity.

Stable angina

Chest pain from angina can feel like a heart attack. Stable angina affects more than 4% of adults and leads to significant reduction in quality of life.

Heart failure with preserved ejection fraction

Heart failure is a clinical syndrome characterized by the inability of the heart to sufficiently pump blood to meet the body’s metabolic needs.

You Are About to Leave Imbria Pharmaceuticals

The appearance of external hyperlinks does not constitute endorsement by Imbria Pharmaceuticals of the linked websites, or the information, products or services contained therein.

Back Continue